BlueRock Therapeutics to start cell therapy trial for Parkinson’s disease 8th April 2021 (Last Updated April 8th, 2021 18:15)
BlueRock Therapeutics is all set to initiate Phase I Study of MSK-DA01 Cell Therapy for advanced Parkinson’s disease (PD) after it received permission from Health Canada.
The trial plans to enrol ten patients in the US and Canada. Credit: National Institute on Aging, National Institutes of Health.
Share Article
BlueRock Therapeutics is all set to initiate Phase I Study of MSK-DA01 Cell Therapy for advanced Parkinson’s disease (PD) after it received permission from Health Canada.
A progressive neurodegenerative disorder, PD is caused by damage to nerve cell in the brain, causing lower dopamine levels. The deterioration of motor and non-motor symptoms is because of dopamine-producing neuron loss.
The Big Ten is winning when it comes to football and basketball, but failing basic economics.
An overwhelming majority of large research institutions in the Big Ten and other schools in the geographic region are falling behind their peers in other regions and it’s hurting all of us.
During the last decade, Michigan held its own as the country’s second-largest academic research institution, according to data released in January by the National Science Foundation. But consider the declines.
Wisconsin fell five spots to eighth; Pittsburgh and Minnesota fell four each to 15th and 17th; Penn State and Ohio State fell nine each to 23th and 25th; Washington University, St. Louis fell 10 to 28th; Northwestern fell three to 29th; Illinois fell four to 38th; Purdue fell eight to 40th; and the University of Chicago fell 16 to 56th.
Bayer AG
Published Jan. 21, 2021
Share it
Large pharmaceutical companies have made gene therapy a priority with a series of acquisitions over the past several years, a stamp of validation for a field that s pushed through decades of ups and downs.
One of the latest buyers is German healthcare conglomerate Bayer, which in October inked a $2 billion deal for North Carolina gene therapy developer Asklepios Biopharmaceuticals, also known as AskBio.
For Bayer, the acquisition is part of a broader effort to build a gene and cell therapy division. But the deal is just as noteworthy for AskBio, an unusually large, privately held biotech based on the work of one of gene therapy s pioneers, Jude Samulski.
Cell and gene therapies can radically change treatment
13 Jan 2021
Mariecar Jara-Puyod,
Senior Reporter
Cell and gene therapies combined with the burgeoning digital health and artificial intelligence shall remain to be a nucleus and continually pivot the intensely-competitive pharmaceutical industry, accelerating solutions for improved health and better outcomes.
This was emphasised at the “Virtual Pharma Media Day” of the healthcare-agriculture global enterprise Bayer on Wednesday (noon to 2.30 pm, UAE time), attended by 200 journalists from 30 countries. Cell therapy is the delivery or injection of “functioning cells into a patient’s body to achieve a medicinal effect-to prevent, manage or cure a certain illness or to repair and regenerate damaged cells.”
E-Mail
Skokie, IL - The ISSCR is bringing together successful biotech CEOs who have transformed scientific breakthroughs into thriving businesses that are improving human health into one program 7-8 January 2021.
VISION2030 comes at a pivotal moment in regenerative medicine and stem cell science as discovery, translation, and investment intersect.
Thursday, 7 January
STEMCELL Technologies Executive Interview
Interviewed by ISSCR Board Member Valentina Greco, Yale University School of Medicine, USA
STEMCELL Technologies mission is to advance the pursuit of scientific knowledge by supplying high quality, innovative reagents, tools, and services that enable life science research.
Surrozen Executive Interview
Claudia Janda, Princes Máxima Centrum, Netherlands l Surrozen Founder